Beta-Lactams Therapeutic Monitoring in Septic Children-What Target Are We Aiming for? A Scoping Review.

beta-lactams pediatrics pharmacodynamics pharmacokinetics sepsis therapeutic drug monitoring

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2022
Historique:
received: 15 09 2021
accepted: 31 01 2022
entrez: 1 4 2022
pubmed: 2 4 2022
medline: 2 4 2022
Statut: epublish

Résumé

The antimicrobial therapy of sepsis and septic shock should be individualized based on pharmacokinetic/pharmacodynamic (PK/PD) parameters to deliver effective and timely treatment of life-threatening infections. We conducted a literature scoping review to identify therapeutic targets of beta-lactam antibiotics in septic pediatric patients and the strategies that have been applied to overcome sepsis-related altered pharmacokinetics and increase target attainment against susceptible pathogens. A systematic search was conducted in the MEDLINE, EMBASE and Web of Science databases to select studies conducted since 2010 with therapeutic monitoring data of beta-lactams in septic children. Last searches were performed on 02 September 2021. Two independent authors selected the studies and extracted the data. A narrative and qualitative approach was used to summarize the findings. Out of the 118 identified articles, 21 met the eligibility criteria. Population pharmacokinetic modeling was performed in 12 studies, while nine studies reported data from bedside monitoring of beta-lactams. Most studies were conducted in the United States of America (

Identifiants

pubmed: 35359889
doi: 10.3389/fped.2022.777854
pmc: PMC8960241
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

777854

Informations de copyright

Copyright © 2022 Morales Junior, Pereira, Tiguman, Juodinis, Telles, de Souza and Santos.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Pediatr Infect Dis J. 2020 Aug;39(8):725-729
pubmed: 32235247
Clin Pharmacokinet. 2018 Jul;57(7):867-875
pubmed: 28980166
Clin Infect Dis. 2014 Apr;58(8):1072-83
pubmed: 24429437
Int J Infect Dis. 2021 Jul;108:102-108
pubmed: 34029707
Pharmacotherapy. 2006 Sep;26(9):1320-32
pubmed: 16945055
Pharmacotherapy. 2021 Feb;41(2):220-233
pubmed: 33480024
J Antimicrob Chemother. 2014 May;69(5):1416-23
pubmed: 24443514
Pediatr Crit Care Med. 2020 Feb;21(2):e52-e106
pubmed: 32032273
Crit Care Med. 2018 Feb;46(2):272-279
pubmed: 29112080
J Antimicrob Chemother. 2020 Aug 1;75(8):2232-2239
pubmed: 32457995
Crit Care. 2019 Mar 29;23(1):104
pubmed: 30925922
Antimicrob Agents Chemother. 2015 Nov;59(11):7027-35
pubmed: 26349821
Pediatr Crit Care Med. 2014 Nov;15(9):798-805
pubmed: 25162514
Arch Dis Child. 2020 Dec;105(12):1208-1214
pubmed: 32404437
Intensive Care Med. 2014 Mar;40(3):380-7
pubmed: 24356862
Eur J Pharm Sci. 2021 Aug 1;163:105868
pubmed: 33951483
J Clin Pharmacol. 2016 Jan;56(1):56-66
pubmed: 26096377
Clin Microbiol Infect. 2019 Mar;25(3):383.e1-383.e4
pubmed: 30528370
Pediatr Crit Care Med. 2016 Aug;17(8):727-34
pubmed: 27362850
J Antimicrob Chemother. 2017 Oct 1;72(10):2891-2897
pubmed: 29091190
J Antimicrob Chemother. 2017 Jul 1;72(7):2002-2011
pubmed: 28387840
Clin Pharmacokinet. 2019 Feb;58(2):223-233
pubmed: 29862466
Crit Care Med. 2009 Mar;37(3):840-51; quiz 859
pubmed: 19237886
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Antimicrob Chemother. 2021 Feb 11;76(3):699-709
pubmed: 33188385
Pharmacotherapy. 2015 Apr;35(4):e32-6
pubmed: 25884534
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098
pubmed: 31802119
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6626-6634
pubmed: 27572399
J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):262-76
pubmed: 25762871
Int J Antimicrob Agents. 2008 Apr;31(4):345-51
pubmed: 18313273
J Pediatr Pharmacol Ther. 2017 Nov-Dec;22(6):467-470
pubmed: 29290748
Pediatr Crit Care Med. 2018 Jun;19(6):e292-e299
pubmed: 29419605
J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):276-285
pubmed: 28943823
Crit Care. 2014 Jun 23;18(3):227
pubmed: 25042938
Ther Drug Monit. 2022 Feb 1;44(1):112-120
pubmed: 34798631
Crit Care Explor. 2021 Jun 11;3(6):e0446
pubmed: 34136822
Pediatr Infect Dis J. 2014 Feb;33(2):168-73
pubmed: 23907263
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S108-S122
pubmed: 30248202
Antimicrob Agents Chemother. 2015 Nov 09;60(1):522-31
pubmed: 26552978
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1255-1260
pubmed: 30968258
Crit Care. 2017 Nov 14;21(1):276
pubmed: 29137682
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28717035
J Infect Dis. 2020 Jul 21;222(Suppl 2):S132-S141
pubmed: 32691832
Lancet Infect Dis. 2019 Dec;19(12):1299-1311
pubmed: 31563344
Clin Microbiol Infect. 2021 Mar;27(3):413-419
pubmed: 32360445

Auteurs

Ronaldo Morales Junior (R)

Clinical Pharmacokinetics Center, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Pediatric Intensive Care Unit, Department of Pediatrics, Hospital Sírio-Libanês, São Paulo, Brazil.

Gabriela Otofuji Pereira (GO)

Clinical Pharmacokinetics Center, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.

Gustavo Magno Baldin Tiguman (GMB)

Faculty of Pharmaceutical Sciences, State University of Campinas, São Paulo, Brazil.

Vanessa D'Amaro Juodinis (VD)

Pediatric Intensive Care Unit, Department of Pediatrics, Hospital Sírio-Libanês, São Paulo, Brazil.

João Paulo Telles (JP)

Department of Infectious Diseases, AC Camargo Cancer Center, São Paulo, Brazil.

Daniela Carla de Souza (DC)

Pediatric Intensive Care Unit, Department of Pediatrics, Hospital Sírio-Libanês, São Paulo, Brazil.
Pediatric Intensive Care Unit, University Hospital, University of São Paulo, São Paulo, Brazil.

Silvia Regina Cavani Jorge Santos (SRCJ)

Clinical Pharmacokinetics Center, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.

Classifications MeSH